A Phase 2 interventional study of Pirfenidone in Systemic Sclerosis, sponsored by Genentech, Inc.. Completed at 22 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-04.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.
Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 50th largest by enrollment of the 142 interventional ones that give a count, is one of 4 that started in 2013, is one of 54 in phase 2, and was the 60th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
Fate Therapeutics · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 42 more countries
Ages 18+
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 74 · Phase 3 17 · Phase 4 3
First in 1992; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 34 across the 142 interventional studies, 67 across the 22 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 165 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 4 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
15 of the studies in Scleroderma, Systemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT04380831City of Hope Medical CenterTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | 2026-12-22 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Scleroderma, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PSSc-001 (LOTUSS)
This study is a Phase 2, multinational, open-label, randomized, parallel-group, safety and tolerability study of pirfenidone in participants with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day \[mg/day\]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
Drug: Pirfenidone
Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
Drug: Pirfenidone
Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)
Percentage of participants who had treatment-emergent AEs, defined as newly occurring or worsening after first dose. Relatedness to (study drug) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
Time frame: From baseline up to 28 days after the last dose of study drug (last dose = Week 16)
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From baseline up to 28 days after the last dose of study drug (last dose = Week 16)
University of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium (SCTC) Gastrointestinal Trial (GIT) Questionnaire Scale Scores
UCLA SCTC GIT Scale 2.0 is a 34-item self-administered questionnaire to obtain participant's assessment of the frequency of GI symptoms in preceding 7 days and how symptoms affected his/her life. All but 2 items were scored on a 0 to 3 scale (0=better health, 3=worse health); remaining 2 items were scored as 0 (better health) and 1 (worse health). The 34 items are divided into seven scales (reflux, distention/bloating, fecal soilage, diarrhea, social functioning, emotional well-being, and constipation). Individual scale score was calculated as the average of the items in the scale. Individual scale score ranged from 0 to 3 for reflux, distention/bloating, fecal soilage, social functioning, and emotional well-being; 0 to 2 for diarrhea; and 0 to 2.5 for constipation. A total score was also calculated as the average of 6 of the 7 scales (omitting constipation) and ranged from 0 to 2.83. For individual and total scores 0 indicated better health and higher score indicates worse health.
Time frame: Baseline, Weeks 4, 8, 12, and 16
| Milestone | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group |
|---|---|---|
| Started | 32 | 31 |
| Completed | 27 | 29 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Percentage of participants who had treatment-emergent AEs, defined as newly occurring or worsening after first dose. Relatedness to (study drug) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
| percentage of participants | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group |
|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (AEs) | 96.9 | 96.8 |
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| percentage of participants | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group |
|---|---|---|
| Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) | 9.4 | 0.0 |
UCLA SCTC GIT Scale 2.0 is a 34-item self-administered questionnaire to obtain participant's assessment of the frequency of GI symptoms in preceding 7 days and how symptoms affected his/her life. All but 2 items were scored on a 0 to 3 scale (0=better health, 3=worse health); remaining 2 items were scored as 0 (better health) and 1 (worse health). The 34 items are divided into seven scales (reflux, distention/bloating, fecal soilage, diarrhea, social functioning, emotional well-being, and constipation). Individual scale score was calculated as the average of the items in the scale. Individual scale score ranged from 0 to 3 for reflux, distention/bloating, fecal soilage, social functioning, and emotional well-being; 0 to 2 for diarrhea; and 0 to 2.5 for constipation. A total score was also calculated as the average of 6 of the 7 scales (omitting constipation) and ranged from 0 to 2.83. For individual and total scores 0 indicated better health and higher score indicates worse health.
| units on a scale | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group |
|---|---|---|
| Reflux: Baseline (n=32, 31) | 0.3398 ± 0.34083 | 0.3347 ± 0.29117 |
| Reflux: Week 4 (n=32, 31) | 0.4727 ± 0.43270 | 0.3548 ± 0.36529 |
| Reflux: CFB Week 4 (n=32, 31) | 0.1328 ± 0.36469 | 0.0202 ± 0.26437 |
| Reflux: Week 8 (n=32, 31) | 0.4660 ± 0.39881 | 0.4389 ± 0.46573 |
| Reflux: CFB Week 8 (n=32, 31) | 0.1261 ± 0.36875 | 0.1043 ± 0.41664 |
| Reflux: Week 12 (n=27, 30) | 0.4306 ± 0.41069 | 0.3417 ± 0.33142 |
| Reflux: CFB Week 12 (n=27, 30) | 0.0880 ± 0.35494 | 0.0042 ± 0.26155 |
| Reflux: Week 16 (n=25, 28) | 0.3950 ± 0.37270 | 0.3348 ± 0.39682 |
| Reflux: CFB Week 16 (n=25, 28) | 0.0750 ± 0.25259 | -0.0045 ± 0.31820 |
| Distention/Bloating: Baseline (n=32, 31) | 0.3984 ± 0.57100 | 0.5968 ± 0.58693 |
| Distention/Bloating: Week 4 (n=32, 31) | 0.6406 ± 0.65049 | 0.4919 ± 0.65346 |
| Distention/Bloating: CFB Week 4 (n=32, 31) | 0.2422 ± 0.41874 | -0.1048 ± 0.50734 |
| Distention/Bloating: Week 8 (n=32,31) | 0.5703 ± 0.60985 | 0.4247 ± 0.57188 |
| Distention/Bloating: CFB Week 8 (n=32, 31) | 0.1719 ± 0.47280 | -0.1720 ± 0.43245 |
| Distention/Bloating: Week 12 (n=27, 30) | 0.5370 ± 0.70610 | 0.4250 ± 0.56152 |
| Distention/Bloating: CFB Week 12 (n=27, 30) | 0.2130 ± 0.59929 | -0.1833 ± 0.47766 |
| Distention/Bloating: Week 16 (n=25, 28) | 0.4800 ± 0.61627 | 0.4286 ± 0.48523 |
| Distention/Bloating: CFB Week 16 (n=25, 28) | 0.1200 ± 0.45139 | -0.1518 ± 0.45307 |
| Diarrhea: Baseline (n=32, 31) | 0.3281 ± 0.48542 | 0.2742 ± 0.48026 |
| Diarrhea: Week 4 (n=32, 31) | 0.3125 ± 0.48775 | 0.2258 ± 0.48026 |
| Diarrhea: CFB Week 4 (n=32, 31) | -0.0156 ± 0.57480 | -0.0484 ± 0.43503 |
| Diarrhea: Week 8 (n=32, 31) | 0.2813 ± 0.37968 | 0.3226 ± 0.55600 |
| Diarrhea: CFB Week 8 (n=32, 31) | -0.0469 ± 0.46419 | 0.0484 ± 0.58245 |
| Diarrhea: Week 12 (n=27, 30) | 0.2778 ± 0.46685 | 0.2000 ± 0.48423 |
| Diarrhea: CFB Week 12 (n=27, 30) | -0.0556 ± 0.56045 | -0.0667 ± 0.58329 |
| Diarrhea: Week 16 (n=25, 28) | 0.3400 ± 0.51478 | 0.2500 ± 0.51819 |
| Diarrhea: CFB Week 16 (n=25, 28) | 0.0400 ± 0.57591 | -0.0179 ± 0.61587 |
| Social Functioning: Baseline (n=32, 31) | 0.1250 ± 0.28078 | 0.1893 ± 0.43585 |
| Social Functioning: Week 4 (n=32, 31) | 0.1563 ± 0.26072 | 0.1775 ± 0.27199 |
| Social Functioning: CFB Week 4 (n=32, 31) | 0.0313 ± 0.25893 | -0.0118 ± 0.28143 |
| Social Functioning: Week 8 (n=32, 31) | 0.1886 ± 0.31322 | 0.1936 ± 0.33647 |
| Social Functioning: CFB Week 8 (n=32, 31) | 0.0635 ± 0.29233 | 0.0044 ± 0.37997 |
| Social Functioning: Week 12 (n=27, 30) | 0.1173 ± 0.23488 | 0.1944 ± 0.30028 |
| Social Functioning: CFB Week 12 (n=27, 30) | 0.0432 ± 0.25154 | -0.0011 ± 0.35730 |
| Social Functioning: Week 16 (n=25, 28) | 0.0600 ± 0.13502 | 0.1667 ± 0.27596 |
| Social Functioning: CFB Week 16 (n=25, 28) | 0.0133 ± 0.16607 | -0.0131 ± 0.40515 |
| Emotional Wellbeing: Baseline (n=32, 31) | 0.0937 ± 0.26033 | 0.1326 ± 0.41910 |
| Emotional Wellbeing: Week 4 (n=32, 30) | 0.0937 ± 0.21697 | 0.0778 ± 0.32516 |
| Emotional Wellbeing: CFB Week 4 (n=32, 30) | 0.0000 ± 0.17831 | -0.0593 ± 0.14808 |
| Emotional Wellbeing: Week 8 (n=32, 31) | 0.1181 ± 0.33273 | 0.0825 ± 0.29680 |
| Emotional Wellbeing: CFB Week 8 (n=32, 31) | 0.0243 ± 0.11887 | -0.0502 ± 0.19846 |
| Emotional Wellbeing: Week 12 (n=27, 30) | 0.0493 ± 0.13182 | 0.0852 ± 0.30979 |
| Emotional Wellbeing: CFB Week 12 (n=27, 30) | 0.0123 ± 0.12055 | -0.0482 ± 0.14786 |
| Emotional Wellbeing: Week 16 (n=25, 28) | 0.0266 ± 0.08030 | 0.0833 ± 0.39959 |
| Emotional Wellbeing: CFB Week 16 (n=25, 28) | 0.0000 ± 0.10627 | -0.0357 ± 0.12851 |
| Fecal Soilage: Baseline (n=32, 31) | 0.0313 ± 0.17678 | 0.1290 ± 0.42755 |
| Fecal Soilage: Week 4 (n=32, 31) | 0.0313 ± 0.17678 | 0.1290 ± 0.42755 |
| Fecal Soilage: CFB Week 4 (n=32, 31) | 0.0000 ± 0.00000 | 0.0000 ± 0.00000 |
| Fecal Soilage: Week 8 (n=32, 31) | 0.0313 ± 0.17678 | 0.1613 ± 0.45437 |
| Fecal Soilage: CFB Week 8 (n=32, 31) | 0.0000 ± 0.00000 | 0.0323 ± 0.17961 |
| Fecal Soilage: Week 12 (n=27, 30) | 0.0370 ± 0.19245 | 0.1333 ± 0.43417 |
| Fecal Soilage: CFB Week 12 (n=27, 30) | 0.0370 ± 0.19245 | 0.0000 ± 0.00000 |
| Fecal Soilage: Week 16 (n=25, 28) | 0.0400 ± 0.20000 | 0.1071 ± 0.41627 |
| Fecal Soilage: CFB Week 16 (n=25, 28) | 0.0400 ± 0.20000 | 0.0000 ± 0.00000 |
| Constipation: Baseline (n=32, 31) | 0.2422 ± 0.40899 | 0.1694 ± 0.26130 |
| Constipation: Week 4 (n=32, 30) | 0.2656 ± 0.34159 | 0.1500 ± 0.29066 |
| Constipation: CFB Week 4 (n=32, 30) | 0.0234 ± 0.42293 | -0.0250 ± 0.30336 |
| Constipation: Week 8 (n=32, 31) | 0.2578 ± 0.39901 | 0.1613 ± 0.46345 |
| Constipation: CFB Week 8 (n=32, 31) | 0.0156 ± 0.25350 | -0.0081 ± 0.38989 |
| Constipation: Week 12 (n=27, 30) | 0.2407 ± 0.38904 | 0.2111 ± 0.36075 |
| Constipation: CFB Week 12 (n=27, 30) | 0.0370 ± 0.37148 | 0.0528 ± 0.49008 |
| Constipation: Week 16 (n=25, 28) | 0.1800 ± 0.29333 | 0.1518 ± 0.27504 |
| Constipation: CFB Week 16 (n=25, 28) | 0.0200 ± 0.37444 | -0.0179 ± 0.42453 |
| Total Score: Baseline (n=32, 31) | 0.2194 ± 0.24262 | 0.2761 ± 0.32679 |
| Total Score: Week 4 (n=32, 31) | 0.2845 ± 0.28528 | 0.2432 ± 0.31264 |
| Total Score: CFB Week 4 (n=32, 31) | 0.0651 ± 0.20058 | -0.0330 ± 0.13591 |
| Total Score: Week 8 (n=32, 31) | 0.2759 ± 0.26133 | 0.2706 ± 0.29132 |
| Total Score: CFB Week 8 (n=32, 31) | 0.0564 ± 0.15749 | -0.0055 ± 0.20053 |
| Total Score: Week 12 (n=27, 30) | 0.2416 ± 0.25329 | 0.2299 ± 0.27136 |
| Total Score: CFB Week 12 (n=27, 30) | 0.0564 ± 0.16790 | -0.0492 ± 0.17709 |
| Total Score: Week 16 (n=25, 28) | 0.2237 ± 0.19767 | 0.2284 ± 0.26906 |
| Total Score: CFB Week 16 (n=25, 28) | 0.0481 ± 0.14444 | -0.0372 ± 0.20737 |
Collected over From baseline up to 28 days after the last dose of study drug (last dose = Week 16). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone: 2-Week Titration Group | — | 3/32 (9.4%) | 31/32 (96.9%) |
| Pirfenidone: 4-Week Titration Group | — | 0/31 (0%) | 30/31 (96.8%) |
| Event | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group |
|---|---|---|
| BronchitisInfections and infestations | 1/32 | 0/31 |
| Small intestinal obstructionGastrointestinal disorders | 1/32 | 0/31 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/32 | 0/31 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 1/32 | 0/31 |
| Event | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group |
|---|---|---|
| NauseaGastrointestinal disorders | 16/32 | 15/31 |
| HeadacheNervous system disorders | 14/32 | 14/31 |
| FatigueGeneral disorders | 13/32 | 10/31 |
| DiarrhoeaGastrointestinal disorders | 9/32 | 10/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/32 | 4/31 |
| VomitingGastrointestinal disorders | 9/32 | 9/31 |
| RashSkin and subcutaneous tissue disorders | 8/32 | 5/31 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 6/32 | 7/31 |
| AstheniaGeneral disorders | 2/32 | 5/31 |
| DizzinessNervous system disorders | 5/32 | 5/31 |
Safety population included all randomized participants who provided written informed consent and received at least one dose of study medication.
| Age, Continuous(years) | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group | Total |
|---|---|---|---|
| Mean | 49.3 ± 12.08 | 51.9 ± 12.52 | 50.6 ± 12.27 |
| Sex: Female, Male(Participants) | Pirfenidone: 2-Week Titration Group | Pirfenidone: 4-Week Titration Group | Total |
|---|---|---|---|
| Female | 26 | 26 | 52 |
| Male | 6 | 5 | 11 |
The record gives a start of Oct 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone